Treatment with amoxiciliin and omeprazole resulted in encouraging Helicobacter pyloon eradication rates in pilot studies that included medium term foliow up. These results were evaluated in a prospective, randomised and controlled study. Forty patients with active duodenal ulcer disease and H pylon colonisation of the gastric mucosa were randomly assigned to receive either omeprazole (20 mg twice daily) and amoxiciflin suspension (500 mg four times daily) for two weeks (group I) or bismuth subsalicylate (600 mg three times daily), metronidazole (400 mg three times daily), tetracycline (500 mg three times daily), and raniditine (300 mg in the evening) for two weeks (group II). Study medication was followed in both groups by a four week treat-
eradication rates in pilot studies that included medium term foliow up. These results were evaluated in a prospective, randomised and controlled study. Forty patients with active duodenal ulcer disease and H pylon colonisation of the gastric mucosa were randomly assigned to receive either omeprazole (20 mg twice daily) and amoxiciflin suspension (500 mg four times daily) for two weeks (group I) or bismuth subsalicylate (600 mg three times daily), metronidazole (400 mg three times daily), tetracycline (500 mg three times daily), and raniditine (300 mg in the evening) for two weeks (group II). Study medication was followed in both groups by a four week treatment course with 300 mg ranitidine up to the final examination. One patient from each group was lost to foliow up. H pylon was eradicated in 78-9% of group I and 84-2% 'of group II (p=1O00). AU ulcers in patients on omeprazole plus amoxicillin healed but in the triple treatment group four patients had residual peptic lesions after six weeks (ulcer healing rate: 78-9%, p=0ll). Complete pain relief occurred after a median duration of 1 day in group I and of 6 days in group II (p=003). There were no major complications in either group but minor side effects were more frequently recorded in patients on triple therapy (63.2% v 15-8%, p<OOl). In (Tables I and II) were randomly assigned to receive either omeprazole (20 mg twice daily) (Antra, Astra Chemicals, Wedel/Holstein, Germany) before meals and amoxicillin suspension (500 mg four times daily) (Amoxypen suspension, Grunenthal, Stolberg, Germany) before meals and at bedtime for two weeks (group I) or bismuth subsalicylate (600 mg three times daily) (Jatrox, Rohm Pharma, Weiterstadt, Germany) before meals, metronidazole (400 mg three times daily) (Clont 400, Bayer, Leverkusen, Germany) and tetracycline (500 mg three times daily) (Hostacyklin 500, Hoechst, Frankfurt, Germany) after meals, and ranitidine (300 mg at night) for two weeks (group II). After stopping the study medication all patients in both groups continued treatment with 300 mg ranitidine at bedtime for four weeks up to the final follow up examination.
Before starting treatment patients were talked to and were given an information sheet on the basic concepts of the pathophysiology ofH pylori infection. They were then asked to participate after a full explanation of the aims and methods of the study, and all gave informed consent. During treatment, patients were asked to consult their study physician if they had side effects. In addition, complaints and side effects were recorded in a diary. Patient 
